Nuclear medicine

Stellantis and Orano Enter Electric Vehicle Battery Recycling Agreement

Retrieved on: 
Tuesday, October 24, 2023
Documentation, Nuclear medicine, European Commission, Battery, Metal, Carbon, Original equipment manufacturer, Nickel, Investment, R, Cobalt, Lithium, Partnership, Recycling, Magnet, Rare-earth element, Renewable energy, Innovation, Orano, Stellantis

It enables OEMs to reach European Commission levels of recycling rate into batteries of electric vehicles and ensure the sustainability of the business model.

Key Points: 
  • It enables OEMs to reach European Commission levels of recycling rate into batteries of electric vehicles and ensure the sustainability of the business model.
  • “We are delighted with this partnership with a major player such as Stellantis to work together in the recycling of used electric batteries,” said Orano Group Director of Innovation, R&D and Nuclear Medicine, Magnets and Batteries, Guillaume Dureau.
  • The new commercial recycling entity will also provide Stellantis’ partners, its after-sales network, and other OEMs with a solution to manage end-of-life batteries and scrap from gigafactories.
  • Investments to reskill and upskill Stellantis and Orano employees will open sustainable perspectives for people in their new assignments.

ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics

Retrieved on: 
Tuesday, October 24, 2023
Forum, AIIMS, Deutsche Gesellschaft für Qualität, Science, Therapy, Medicine, ITM, Physician, RPT, Cross, Research, Radiopharmaceutical, ICPO, Growth, International Center for Ethnobotanical Education, Research and Service, RPO, Partnership, Hospital, GIZ, All India Institute of Medical Sciences, Jodhpur, Cancer, Actinium-225, Nuclear medicine, Patient, Nursing, Diagnosis, Associate, Medical imaging, Pharmaceutical industry

The company also announced support for the ICPO’s newly established Academy for Theranostics, which was unveiled as part of the event.

Key Points: 
  • The company also announced support for the ICPO’s newly established Academy for Theranostics, which was unveiled as part of the event.
  • The hosting organization, ICPO is an independent German foundation working on progressing access to Radiomolecular Precision Oncology (RPO) diagnostics and treatments for cancer patients globally.
  • Company representatives also presented the esteemed Maurits W. Geerlings Next Generation Award and contributed to the launch of the ICPO Academy for Theranostics.
  • ITM also announced its support for the ICPO Academy for Theranostics , which was unveiled at the event.

ICPO Foundation Announcing Official Launch of Its ICPO Academy for Theranostics During Its 3rd Forum for Theranostics in Precision Oncology on October 12th and 13th in Garching Munich

Retrieved on: 
Tuesday, October 24, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Health Technology, Pillar, Linda, Knowledge, Patient, Forum, Faculty, Education, Global public–private partnership, Deutsche Gesellschaft für Internationale Zusammenarbeit, Medicine, ITM, Organization, Accreditation, Public–private partnership, Geography, ICPO, University of Puerto Rico, Medical Sciences Campus, Curriculum, Meridian International Center, Partner, GIZ, Community, Nursing, Nuclear medicine, Cancer

This October 12th and 13th, 2023, the International Centers for Precision Oncology (ICPO) Foundation has successfully hosted its 3rd ICPO Forum for Theranostics in Precision Oncology physical on the Science Campus in Garching Munich.

Key Points: 
  • This October 12th and 13th, 2023, the International Centers for Precision Oncology (ICPO) Foundation has successfully hosted its 3rd ICPO Forum for Theranostics in Precision Oncology physical on the Science Campus in Garching Munich.
  • At the occasion of its 3rd Forum, the ICPO Foundation has officially launched its ICPO Academy for Theranostics.
  • The ICPO Academy for Theranostics offers a comprehensive online educational programme, developed by the ICPO Foundation and powered by its global Community of experts.
  • Moreover, to make a donation or become a Member of the ICPO Foundation, as Friend, Supporter or Partner, please visit www.icpo.foundation .

Hemet Global Medical Center Voted “Best Hospital” in the Inland Empire by Press-Enterprise Readers for 2023

Retrieved on: 
Tuesday, October 17, 2023
Hospital, Acquisition, Pastoral Care, CT scan, Hospital Insurance and Diagnostic Services Act, Bankruptcy, ERCP, Urology, Arthroscopy, U.S. News & World Report Best Hospitals Rankings, EKG, TEE, Interventional radiology, Health, The Press-Enterprise, Medical-surgical nursing, EEG, Prenatal development, Nursing, Emergency service, KPC, Minimally invasive spine surgery, Lactation consultant, Nuclear medicine, EGD, MRI, ICU, Professional, Social work, Patient, Pound (currency), Mammography, Echocardiography, Bronchoscopy, Cardiology, Ultrasound, Telemetry, Inland Empire, Colonoscopy

ORANGE, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Hemet Global Medical Center (“HGMC”), a KPC Health hospital, has been voted “Best Hospital” in the Inland Empire for 2023 by Press-Enterprise readers.

Key Points: 
  • ORANGE, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Hemet Global Medical Center (“HGMC”), a KPC Health hospital, has been voted “Best Hospital” in the Inland Empire for 2023 by Press-Enterprise readers.
  • The distinguished honor is part of the Press-Enterprise’s 28th Annual “Best of Inland Empire” Readers’ Choice awards for local businesses.
  • “Prior to KPC Health’s acquisition of Hemet Global Medical Center, this was a hospital on the brink of bankruptcy that many believed could not be saved,” said Dr. Kali P. Chaudhuri, Founder and Chairman of the KPC Group.
  • KPC Health’s current system of hospitals includes seven full-service acute care hospitals located throughout southern California, including Orange County Global Medical Center, Chapman Global Medical Center, Anaheim Global Medical Center, South Coast Global Medical Center, Hemet Global Medical Center, Menifee Global Medical Center, and Victor Valley Global Medical Center.

Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)

Retrieved on: 
Friday, October 13, 2023
ALS, Positron emission tomography, Nuclear medicine, Coronavirus Scientific Advisory Board, Mass, PET, Hospital, Disease, Expanded access, Patient, FDA, Special access program, Microglia, Neurology, Harvard Medical School, Assistant, Multiple sclerosis, DSM-IV codes, Microsoft Access, EAP, Medical imaging, Brigham

Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis, or ALS.

Key Points: 
  • Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis, or ALS.
  • When combined with my assessment of the first two Expanded Access patients at six-months, five of the six suggested a reduction in qualitative microglial PET signal.
  • An example of this can be seen in the graphic below, titled, “Figure 1”, showing the deactivation of this signal in patient EA6.
  • This is promising from an imaging standpoint, and further studies are needed to confirm these findings using additional quantitative approaches."

GE HealthCare and University Hospitals Enter 10-Year Strategic Collaboration to Contemporize Its Imaging Fleet and Implement Enterprise Digital Solutions to Help Improve Patient Care and Optimize Processes

Retrieved on: 
Thursday, October 5, 2023
Managed Care, Other Health, Radiology, Pharmaceutical, Data Management, Technology, University, Artificial Intelligence, Health Technology, Education, Cardiology, Other Technology, Health, Multimedia, MBA, Physician, Student, Machine learning, University Hospitals Cleveland Medical Center, AI, MD, Nuclear medicine, Command center, Workflow, CT, UH, GE HealthCare, GE, Software, Overalls, Patient, Fluoroscopy, Medical imaging, Nursing, Medical device

A focus of the collaboration is to implement enterprise-wide technology to optimize workflows and help improve clinical decision-making.

Key Points: 
  • A focus of the collaboration is to implement enterprise-wide technology to optimize workflows and help improve clinical decision-making.
  • These issues underscore the need for more efficient workflows and a real-time decision-making solution to optimize hospital operations and patient care.
  • Standardization and automated protocols across CT devices to help improve workflow, increase utilization and reduce the downtime associated with managing the fleet.
  • A digital Command Center solution that leverages technology and insights at the enterprise-level through a cloud-based digital hub for UH’s radiology department.

Claritas HealthTech (Claritas) and Paragon Health IT (Paragon) Announce Strategic Partnership to Deliver AI Tools, Medical Image Processing , and Data Services to Global Medical Imaging Centers

Retrieved on: 
Tuesday, October 3, 2023
Partnership, CTS, Radiology, PET, Joint Chemical, Biological, Radiological and Nuclear Regiment, Nuclear medicine, Magnetic resonance imaging, Hospital, Irad, Acquisition, Automation, Physician, Algorithm, AI, RSNA, FDA, Goddess, X-ray, Medical imaging, Medical device, Paragon, String, Times New Roman

The synergies achieved will enable hospitals and imaging centres globally to easily adopt and utilize Claritas’ image processing technologies, together with Paragon’s streamlined data services, resulting in improved patient outcomes and efficient clinical workflows.

Key Points: 
  • The synergies achieved will enable hospitals and imaging centres globally to easily adopt and utilize Claritas’ image processing technologies, together with Paragon’s streamlined data services, resulting in improved patient outcomes and efficient clinical workflows.
  • Claritas, a company specializing in medical image enhancement and AI Diagnostic Tools, aims to deliver its FDA-Cleared software products for Radiology and Nuclear medicine through this platform to customers across North America.
  • Strings, created by Paragon, has data pipelines that are at the forefront of healthcare data management.
  • Chetan Baxi, CEO of Claritas, commented, “Our image enhancement and reconstruction software solutions provide significant benefits to our customers with improved image quality.

Ariceum Therapeutics' targeted radiopharmaceutical 177Lu-satoreotide exhibits promising clinical response and good tolerability profile in patients with advanced neuroendocrine tumours

Retrieved on: 
Thursday, September 28, 2023
Neutropenia, NETS, Carcinoma, Radiation, Clinical trial, GEP, Somatostatin, Molecular imaging, DCR, Call of the Wild (D-A-D album), Nuclear medicine, Doctor of Philosophy, SCLC, Lymphocytopenia, Patient, Paraganglioma, Cancer, Pheochromocytoma, SSTR2, Diagnosis, Phase, Therapy, Thrombocytopenia, European Journal, Safety, European Journal of Nuclear Medicine and Molecular Imaging, Medical imaging, Pharmaceutical industry, Ipsen

This international study was conducted in 7 countries - Australia, Austria, Canada, Denmark, France, Switzerland, and the UK - and enrolled 40 patients with advanced, SSTR2-positive NETs.

Key Points: 
  • This international study was conducted in 7 countries - Australia, Austria, Canada, Denmark, France, Switzerland, and the UK - and enrolled 40 patients with advanced, SSTR2-positive NETs.
  • The primary tumours of the patients included progressive, grade 1 and 2 (≈60%) gastroenteropancreatic (GEP), and (a)typical lung NETs, paraganglioma, and pheochromocytoma.
  • Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: "These exciting new data demonstrate the great potential of our targeted radiopharmaceutical, satoreotide, for treating patients with advanced neuroendocrine tumours.
  • A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.

Ariceum Therapeutics' targeted radiopharmaceutical 177Lu-satoreotide exhibits promising clinical response and good tolerability profile in patients with advanced neuroendocrine tumours

Retrieved on: 
Thursday, September 28, 2023
Neutropenia, NETS, Carcinoma, Radiation, Clinical trial, GEP, Somatostatin, Molecular imaging, DCR, Call of the Wild (D-A-D album), Nuclear medicine, Doctor of Philosophy, SCLC, Lymphocytopenia, Patient, Paraganglioma, Cancer, Pheochromocytoma, SSTR2, Diagnosis, Phase, Therapy, Thrombocytopenia, European Journal, Safety, European Journal of Nuclear Medicine and Molecular Imaging, Medical imaging, Pharmaceutical industry, Ipsen

This international study was conducted in 7 countries - Australia, Austria, Canada, Denmark, France, Switzerland, and the UK - and enrolled 40 patients with advanced, SSTR2-positive NETs.

Key Points: 
  • This international study was conducted in 7 countries - Australia, Austria, Canada, Denmark, France, Switzerland, and the UK - and enrolled 40 patients with advanced, SSTR2-positive NETs.
  • The primary tumours of the patients included progressive, grade 1 and 2 (≈60%) gastroenteropancreatic (GEP), and (a)typical lung NETs, paraganglioma, and pheochromocytoma.
  • Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: "These exciting new data demonstrate the great potential of our targeted radiopharmaceutical, satoreotide, for treating patients with advanced neuroendocrine tumours.
  • A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.

United Imaging Healthcare debuts Next-Generation PET/CT Systems, the uMI Panorama Family, and the Integrated Molecular Technology Platform at EANM

Retrieved on: 
Thursday, September 21, 2023
Yale University, CE, IPO, University of California, Davis, NX, University, Moses Austin, MI, NEMA, Peking Union Medical College Hospital, EANM, BRAIN, Deep learning, NCI-designated Cancer Center, PET, Brain, Research, Nuclear medicine, Radiopharmaceutical, Washington University in St. Louis, Gold standard, Umi, Huntsman Cancer Institute, Radiation, European Association of Nuclear Medicine, UC, Patient, Molecular imaging, Fudan University, DOI, PET/CT, Artificial intelligence, AdventHealth Celebration, Panorama, Neoplasm, FDA, FOV, AI, Zhongshan Hospital, Medical imaging

VIENNA, Sept. 21, 2023 /PRNewswire/ -- United Imaging Healthcare, a global leader in advanced medical imaging and radiotherapy equipment, introduces its next-generation PET/CT systems, the uMI Panorama™, and the integrated molecular technology platform named uExcel, at the European Association of Nuclear Medicine (EANM) 2023 annual meeting taking place from September 9-12 in Vienna, Austria. As the sponsor of the "EANM Young Authors' Award" and "EANM Technologist Award" this year, United Imaging is playing a significant role in driving innovation in the field of molecular imaging and nuclear medicine on a global scale.

Key Points: 
  • The new wide-bore uMI Panorama is a family of products that includes the uMI Panorama, the uMI Panorama GS, and the NeuroEXPLORER.
  • The uMI Panorama GS, deriving its name from the term "Gold Standard", was born to set the gold standard in molecular imaging and revolutionize whole-body PET imaging.
  • In tandem with uMI Panorama, the uExcel, is an advanced molecular imaging technology platform meticulously integrated with both hardware and software components.
  • (Note: The uMI Panorama and the uMI Panorama GS are CE pending, not commercially available yet.